NASDAQ:BNR

Burning Rock Biotech Q4 2024 Earnings Results & Report

Burning Rock Biotech logo
$13.07 +0.57 (+4.56%)
Closing price 04:00 PM Eastern
Extended Trading
$13.30 +0.23 (+1.78%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Burning Rock Biotech beat analyst earnings expectations in its Q4 2024 results, released March 25, 2025. The company reported EPS of -$1.08 versus the -$1.3970 consensus estimate, while revenue was $17.27 million.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Burning Rock Biotech EPS Results

Actual EPS
-$1.08
Consensus EPS
-$1.3970
Beat/Miss
Beat by +$0.3170
One Year Ago EPS
N/A

Burning Rock Biotech Revenue Results

Actual Revenue
$17.27 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Burning Rock Biotech Q4 2024 Earnings FAQ

Burning Rock Biotech (NASDAQ:BNR) reported earnings of -$1.08 per share for Q4 2024, beating the consensus estimate of -$1.3970. The report was announced on Tuesday, March 25, 2025.

Burning Rock Biotech reported revenue of $17.27 million for Q4 2024.

Burning Rock Biotech Earnings Headlines

Burning Rock Biotech (BNR) versus Its Competitors Critical Analysis
ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
Burning Rock Biotech (BNR) Projected to Release Earnings on Tuesday
See More Burning Rock Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Burning Rock Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Burning Rock Biotech and other key companies, straight to your email.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ:BNR) is a precision oncology company that develops and provides next-generation sequencing tests for cancer. Its testing uses tissue and blood samples to help inform treatment decisions, monitor disease and support cancer research.

The company also provides research and clinical-trial services to pharmaceutical companies, including support for the development of cancer therapies and diagnostic tests. Burning Rock is headquartered in Guangzhou, China, and its business primarily serves the Chinese healthcare and life sciences markets.

Founded in 2014, Burning Rock focuses on applying genomic testing to cancer care, including the development of tests for treatment selection and disease monitoring.

View Burning Rock Biotech Profile